Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The interleukin-13 receptor (IL-13R) is a type I cytokine receptor that primarily binds interleukin-13 (IL-13), a key cytokine involved in immune regulation, particularly in allergic inflammation and asthma. The functional IL-13 receptor complex is formed by the association of two subunits: IL-13Rα1 and the shared alpha chain, IL-4Rα. Signaling proceeds through activation of Janus kinases (JAKs), leading to phosphorylation and dimerization of STAT proteins—primarily STAT6—which then translocate into the nucleus to regulate target gene expression involved in Th2 immune responses such as allergy and asthma. Therapeutically targeting this pathway has been effective in treating severe allergic diseases due to its pivotal role in driving pathological inflammation.
Inhibition of IL-13 signaling by blocking the interaction of IL-13 with its receptor or by blocking downstream signaling events.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin 13 Receptor (via Shared Alpha Chain) (IL-13R).